BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21168283)

  • 1. Radiosensitizing properties of bortezomib depend on therapeutic schedule.
    Labussière M; Pinel S; Vandamme M; Plénat F; Chastagner P
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):892-900. PubMed ID: 21168283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
    Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].
    Wang QW; Liu H; Liang YM; Wang T; Zhu XD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Jun; 43(6):456-9. PubMed ID: 18826102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
    Labussiere M; Pinel S; Delfortrie S; Plenat F; Chastagner P
    Oncol Rep; 2008 Nov; 20(5):1283-7. PubMed ID: 18949434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
    Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
    Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
    Cusack JC; Liu R; Xia L; Chao TH; Pien C; Niu W; Palombella VJ; Neuteboom ST; Palladino MA
    Clin Cancer Res; 2006 Nov; 12(22):6758-64. PubMed ID: 17121896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Diagaradjane P; Guha S; Deorukhkar A; Shentu S; Aggarwal BB; Krishnan S
    Clin Cancer Res; 2008 Apr; 14(7):2128-36. PubMed ID: 18381954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.
    Kong Z; Raghavan P; Xie D; Boike T; Burma S; Chen D; Chakraborty A; Hsieh JT; Saha D
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1210-8. PubMed ID: 20970033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
    Papadopoulou MV; Bloomer WD; Hollingshead MG
    Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
    Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
    Marchi E; Paoluzzi L; Scotto L; Seshan VE; Zain JM; Zinzani PL; O'Connor OA
    Clin Cancer Res; 2010 Jul; 16(14):3648-58. PubMed ID: 20501616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
    Huang CY; Wei CC; Chen KC; Chen HJ; Cheng AL; Chen KF
    Cancer Lett; 2012 Apr; 317(1):9-15. PubMed ID: 22085493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
    Valentiner U; Haane C; Nehmann N; Schumacher U
    Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.